Curis (NASDAQ:CRIS) Rating Increased to Hold at Wall Street Zen

Curis (NASDAQ:CRIS) was upgraded by Wall Street Zen to a “hold” rating in a research report issued on Saturday.

A number of other brokerages have also recently issued reports on CRIS. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Curis in a report on Friday, March 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $17.00.

Curis Stock Performance

Shares of CRIS opened at $0.56 on Friday. The firm has a market cap of $7.63 million, a PE ratio of -0.47 and a beta of 3.02. The firm’s 50 day moving average price is $0.95 and its 200 day moving average price is $1.21. Curis has a twelve month low of $0.52 and a twelve month high of $3.13.

Curis (NASDAQ:CRIS) last posted its earnings results on Thursday, March 19th. The biotechnology company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $3.25 million. On average, sell-side analysts anticipate that Curis will post -7.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Jane Street Group LLC grew its position in Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after buying an additional 10,586 shares in the last quarter. XTX Topco Ltd acquired a new position in Curis in the 4th quarter valued at approximately $26,000. Warberg Asset Management LLC acquired a new position in Curis in the 3rd quarter valued at approximately $73,000. Squarepoint Ops LLC lifted its position in shares of Curis by 46.2% in the 4th quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 27,343 shares during the period. Finally, Focused Wealth Management Inc grew its holdings in shares of Curis by 33.8% during the 3rd quarter. Focused Wealth Management Inc now owns 79,199 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 19,995 shares in the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.